Agenus Inc. — FY 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. This is an annual report; selected fourth-quarter figures are included below. Agenus is a clinical-stage biopharmaceutical company developing immuno-oncology therapies, including Prophage cancer vaccines, HerpV, checkpoint antibodies, and QS-21 vaccine adjuvant programs conducted largely by partners.
Financial performance and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $3.05 million | $15.96 million |
| Operating expenses: R&D | $13.01 million | $10.56 million |
| Operating expenses: G&A | $14.48 million | $11.47 million |
| Operating loss | $24.98 million | $6.74 million |
| Net loss | $30.07 million | $11.32 million |
| Net loss attributable to common stockholders; loss per share | $33.23 million; $1.12 | $12.12 million; $0.51 |
| Net cash used in operating activities | $19.53 million | $1.01 million provided |
- Revenue fell 80.9% year over year. FY 2012 included one-time payments of $6.5 million from expanded GSK rights and $6.25 million from a license buyout; management cautioned that 2012 revenue and operating cash flow were not indicative of future results.
- R&D spending rose 23.1%, principally reflecting higher HerpV activity and compensation costs. G&A rose 26.3%, mainly due to compensation and professional fees.
- Cash and cash equivalents were $27.35 million at year-end, versus $21.47 million a year earlier. Current assets were $28.17 million and current liabilities $10.30 million.
- Debt principal outstanding was approximately $9.6 million at year-end. The 2013 balance sheet also included an $18.80 million contingent royalty consideration liability related to rights granted to former noteholders.
- Accumulated deficit was $649.1 million; stockholders’ deficit was $4.48 million. No cash dividends have been paid or are anticipated in the foreseeable future.
Fourth quarter: Revenue was $393,000, net loss was $5.78 million, loss attributable to common stockholders was $5.83 million, and basic and diluted loss per share was $0.16.
Material changes and significant events
- In April 2013, Agenus exchanged its $39.0 million 8% convertible notes for $10.0 million cash, 2.5 million common shares, 20% of specified QS-21 revenue interests, and a 0.5% royalty on HerpV net sales. The cash payment was financed with a $5.0 million Silicon Valley Bank loan and $5.0 million of subordinated notes. The exchange generated a $3.3 million extinguishment loss.
- After year-end, Agenus acquired 4-Antibody AG on February 12, 2014, adding a fully human antibody discovery platform and six preclinical checkpoint programs. Consideration included 3.334 million Agenus shares valued at $10 million, potential milestone payments that may exceed $40 million, and assumed obligations and debt.
- In February 2014, Agenus raised approximately $56.0 million net through an offering of 22.236 million common shares. The company said year-end cash, offering proceeds, and potential collaboration proceeds were expected to fund liquidity needs through the first half of 2015.
- For the 2006 note exchange, former noteholders received rights to 20% of certain QS-21 partnered revenues and a 0.5% HerpV royalty, reducing Agenus’s share of potential future proceeds.
Outlook, development and risks
- Management expects continued losses and stated that longer-term funding depends on additional capital, partnerships, licensing, asset sales, or other financing. It may reduce or discontinue programs if funding or development prospects require it. No earnings or revenue guidance was provided.
- HerpV’s Phase 2 trial met its primary endpoint, showing a statistically significant reduction in viral shedding after the initial three injections. Further results following a booster were expected in the first half of 2014; the filing cautions that shedding reduction may not translate into clinical benefit.
- Prophage G-100 and G-200 Phase 2 studies in newly diagnosed and recurrent glioblastoma were fully enrolled. Reported survival and progression-free-survival results were preliminary or compared with historical controls; the randomized G-200/Avastin study was ongoing.
- GSK’s Phase 3 MAGE-A3 melanoma DERMA study failed its first co-primary endpoint in the overall trial population. GSK continued the trial to assess a prespecified gene-signature endpoint, with results anticipated in 2015. Results from its non-small-cell lung cancer Phase 3 program were expected in the first half of 2014.
- Agenus cited substantial risks from clinical and regulatory uncertainty, manufacturing and patient-specific vaccine logistics, reliance on licensees and collaborators, competition, intellectual-property constraints, and the need for future financing. QS-21’s composition-of-matter patent had expired.
- The SVB loan is secured by substantially all company assets and contains restrictive covenants; both the SVB loan and subordinated notes were due in April 2015. The company also reported potential dilution and limited authorized shares following its 2014 financing and acquisition, and planned to seek stockholder approval to increase authorized common shares.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls as of year-end; integration of 4-Antibody’s controls remained a future task.
Key facts for investors to verify
- Whether the 2014 equity proceeds and subsequent cash use support the stated liquidity runway, and what financing is required beyond the first half of 2015.
- Full HerpV booster-trial findings and whether viral-shedding results lead to meaningful clinical benefit.
- Updated, adequately controlled Prophage trial outcomes, including the randomized recurrent-glioblastoma study.
- Partner progress, trial outcomes, regulatory applications, and royalty economics for QS-21 programs—particularly following the MAGE-A3 melanoma result.
- Final accounting and integration impacts of the 4-Antibody acquisition, including contingent milestones, assumed obligations, and potential dilution.
- Debt repayment and covenant compliance, the contingent royalty obligation, and the effect of revenue-sharing rights on future cash receipts.